Main impression: As reported in other works (PMID:26908792, PMID:28182620), immunological recovery and a normalized CD4/CD8 ratio in HIV-infected patients might not be evident, despite effective ART. In addition, CD4 count could not be the only marker of immunological improvement following an effective ART. The article is well written and purposes are elucidated. However, few issues need to be clarified, as below specified. Thus, after a minor revision the manuscript should be considered for publication.
Major comments: In Table 2 differences between HIV-infected individuals with high and low pre-HAART CD8 count are shown. Heterosexual mode of transmission were more likely to have a pre-HAART CD8 count < 800; this feature deserves a comment in the discussion. Moreover, cumulative HIV-RNA viremia has been associated (PMID: 25715104) with a lower likelihood of achieving a normalized CD4/CD8 ratio. A clear evaluation of the impact of cumulative HIV viremia on the achievement of a normalized ratio (>0.8) should be added in table 4 comparing those with optimal immune outcome or conventional outcome.
Minor comments: If data are available, the impact of HCV and/or CMV co-infections (anti-CMV IgG) should be assessed. In fact, as reported in a recent studies HCV (PMID HCV: 26355305, PMID: 27371888) , and CMV (PMID: 26400999 PMID: 27601222), particularly, may alter CD8 count because of persistent immune activation state thus modifying CD4/CD8 ratio. Otherwise, the authors should add these lacking data in the limitations of the study. Of note, all suggested references, should be added to the text.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 1. It is not clear why the authors have chosen a combination of CD4 and CD4/CD8 ratio restoration. They do not state if the combination of these two measurements add any value to the measurement of simply the CD4/CD8 ratio. Previous papers, cited by the authors, have shown that the ratio is a better predictor of overall mortality and development of non AIDS defining events than the CD4 count. If the authors are aware of any report showing that taken together the post-treatment CD4 count and CD4/CD8 ratio predict better the clinical outcomes should include this in the Introduction and Discussion. It would make more meaningful the research. R: Some studies have reported the development of comorbidity in HIV patients despite achieving satisfactory CD4 level following antiretroviral therapy, while a suboptimal CD4/CD8 was shown to be related with HIV associated non-AIDS conditions. The observation motivated us to explore the use of a combined marker to measure immune recovery, using regularly collected investigation results. To date, we could not find any published articles using both CD4 and CD4/CD8 ratio markers to predict clinical outcome. We have added a sentence in INTRODUCTION to explain the non-concurrent rise of CD4/CD8 ratio and CD4 count to strengthen the rationale of using combined marker: "Low CD4/CD8 ratio was observed in patients despite high CD4 level (>500/μL)." [ref 12] 2. Similarly, the authors have chosen a convenience cut-off value for the ratio, i.e. 0.8. Previous reports have shown that a CD4/CD8 ratio=0.4 better predicts the risk of an adverse outcome. As the objective of this manuscript is examining the optimal immune recovery, setting a cut-off of 0.4 for examine the adverse outcome would deviate from the original objective. We agree with the Reviewer to examine the context of a low CD4 count threshold. In response to the comment, we have further classified the distribution of CD4/CD8 ratio into <0.4, 0.4-0.79 and >=0.8 and the corresponding CD4 levels. This is now added as Supplementary Table 2 to show the distribution at baseline and at the end of Year 4. We believe that this would form useful reference for supporting the planning of followup studies.
3. In several parts of the manuscript (conclusion of the abstract, introduction, discussion), the authors state that "our results suggest that a combination of CD4 count and CD4/CD8 ratio provides a better reflection of immune outcome, compared to the reliance on CD4 alone". However, the study does not allow to conclude nothing similar to this statement. It should be rephrased accordingly, especially the conclusion of the abstract. R: The statement has been rephrased in the (a) CONCLUSION: Our results suggested that a combination of CD4 count and CD4/CD8 ratio offers another potentially useful approach to assessing immune outcome, compared to the use of CD4 alone, and ABSTRACT: A combination of CD4 count and CD4/CD8 ratio could be a useful approach for the characterisation of treatment outcome over time, on top of monitoring CD4 count alone.
Reviewer: 2 Major comments: In Table 2 differences between HIV-infected individuals with high and low pre-HAART CD8 count are shown. Heterosexual mode of transmission were more likely to have a pre-HAART CD8 count < 800; this feature deserves a comment in the discussion. Moreover, cumulative HIV-RNA viremia has been associated (PMID: 25715104) with a lower likelihood of achieving a normalized CD4/CD8 ratio. A clear evaluation of the impact of cumulative HIV viremia on the achievement of a normalized ratio (>0.8) should be added in table 4 comparing those with optimal immune outcome or conventional outcome. R: Pre-HAART CD8 was positively correlated (r=0.50, p<0.001) with pre-HAART CD4 (Supplementary Figure 1d) . As heterosexuals had lower pre-HAART CD4 than MSM, they were more likely to have lower pre-HAART CD8 than MSM in univariate analysis, but the difference was not significant after the adjustment by confounder of pre-HAART CD4. We have added a sentence in the DISCUSSION to this effect. We are aware of the association of cumulative HIV-RNA viremia with a lower likelihood of achieving a normalized CD4/CD8 ratio reported in PMID: 25715104 [ref 5 in our manuscript]. The study referred to the outcome of primary HIV infection following antiretroviral therapy, which is different from that of chronic infection examined in this study. We have performed another set of GEE models with cumulative viral load as an independent variable. It was not a significant predictor of an optimal ratio, though the number of patients eligible for the analyses was just 187. The results are not shown in details in the manuscript (see APPENIDIX overleaf)
Minor comments: If data are available, the impact of HCV and/or CMV co-infections (anti-CMV IgG) should be assessed. In fact, as reported in a recent studies HCV (PMID HCV: 26355305, PMID: 27371888) , and CMV (PMID: 26400999 PMID: 27601222), particularly, may alter CD8 count because of persistent immune activation state thus modifying CD4/CD8 ratio. Otherwise, the authors should add these lacking data in the limitations of the study. Of note, all suggested references, should be added to the text. R: We agree that HCV and CMV coinfections could be important factors in shaping immune recovery. Unfortunately, such data were not available for analyses in this study, which we shall definitely consider in future studies. The limitation has been added in the DISCUSSION, alongside the suggested references: ……..our dataset did not include other inflammatory markers or infectious disease outcomes (e.g. HCV and/or CMV co-infections [ref 32-35] ) and therefore these could not be analysed in perspective. 
